Reuters -- Gilead Sciences Inc said on Tuesday its quarterly profit rose a better-than-expected 43 percent on higher sales of its core HIV drugs and royalties on sales of the flu drug Tamiflu, boosting its shares 6 percent.
Reuters -- Gilead Sciences Inc said on Tuesday its quarterly profit rose a better-than-expected 43 percent on higher sales of its core HIV drugs and royalties on sales of the flu drug Tamiflu, boosting its shares 6 percent.
